RxDoctor Payments Data

Richard King, MD

Internal Medicine · Beachwood, OHNPI 1861481350

Payments from drug & device makers

$647in general payments, 2019–2025

Across 17 payments — averaging $38.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hydrocision, Inc.$277
  • Novo Nordisk$143
  • Mannkind Corporation$70
  • Pfizer$56
  • Sanofi-aventis U.S. LLC$41
  • Boehringer Ingelheim$28
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$60493%
  • Education$437%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$647 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$102,581
Medicare patients
139
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban288$104,922
JardianceEmpagliflozin70$49,924
EntrestoSacubitril/Valsartan50$23,651
FarxigaDapagliflozin Propanediol37$23,054
JanuviaSitagliptin Phosphate15$16,478
TrulicityDulaglutide11$14,616
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$13,176
Atorvastatin Calcium680$11,062
XareltoRivaroxaban21$10,663
Mesalamine13$8,460
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$7,773
NamzaricMemantine Hcl/Donepezil Hcl12$7,102
Breo ElliptaFluticasone/Vilanterol15$6,200
Seroquel XrQuetiapine Fumarate11$5,524
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$104,922288 claims
Boehringer IngelheimJardiance$28$49,92470 claims
NovartisEntresto$16$23,65150 claims
Johnson & JohnsonXarelto$16$10,66321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Beachwood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →